Background: Cardiopulmonary bypass (CPB) induces a systemic inflammatory reaction that may contribute to postoperative complications. Preventing this reaction with steroids may improve outcomes. We performed a systematic review to evaluate the impact of prophylactic steroids on clinical outcomes in patients undergoing on-pump cardiac surgery. Methods: We searched MEDLINE, EMBASE, and Cochrane CENTRAL for randomised controlled trials (RCTs) comparing perioperative corticosteroid administration with a control group in adults undergoing CPB. Outcomes of interest included mortality, myocardial infarction, and new onset atrial fibrillation. We assessed the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation approach. Results: Fifty-six RCTs published between 1977 and 2015 were included in this meta-analysis. Mortality was not significantly different between groups [3.0% (215/7258 patients) in the steroid group and 3.5% (252/7202 patients) in the placebo group; relative risk (RR), 0.85; 95% confidence interval (CI), 0.71e1.01; P¼0.07; I 2 ¼ 0%]. Myocardial injury was more
Editor's key points
The authors performed a systematic review/metaanalysis to examine the possibility that steroids might reduce systemic inflammation after cardiac surgery, and improve outcome. The pooled data were derived from more than 16 000 patients, and showed an unclear effect on mortality, while increasing some risks.
Cardiopulmonary bypass (CPB) induces a systemic inflammatory reaction by exposing the blood to foreign surfaces, nonphysiologic flow, and hypothermia. This is exacerbated by the ischemia-reperfusion injury when weaning from CPB. 1e3 This complex inflammatory reaction may contribute to postoperative complications such as ventricular dysfunction and organ failure. 3, 4 Preventing this reaction may improve outcomes after on-pump cardiac surgery. In 2008, a systematic review and meta-analysis of randomised controlled trials (RCTs) evaluated the efficacy and safety of prophylactic steroids in patients undergoing CPB. 5 Even though it included 44 trials (3205 patients), the meta-analysis lacked power for outcomes with lower incidence rates such as mortality [16 trials, 2038 30 -day mortality (RR, 0.88; 95% CI, 0.71e1.09). 6 The reduction in atrial fibrillation suggested in the meta-analysis was not seen in the SIRS trial (RR, 0.97; 95% CI, 0.89e1.06).
The results of the Dexamethasone in Cardiac Surgery (DECS) study (n¼4494) were similar, with no benefit on mortality (RR, 0.92; 95% CI, 0.57e1.49) or atrial fibrillation (RR, 0.94; 95% CI, 0.87e1.02). 7 Although literature has reported that meta-analyses are at risk of overestimating intervention effects, a simulation study performed by Mills and colleagues 8 suggested that once the OIS is reached in a meta-analysis, overestimation is less likely. The primary objective of this systematic review and metaanalysis was to answer the following research question: In patients undergoing on-pump cardiac surgery, is the prophylactic administration of steroids safe and effective in reducing morbidity and mortality?
Methods

Eligibility criteria
We searched for published RCTs comparing perioperative corticosteroid administration with a control group (placebo or standard care) in adults undergoing CPB. Eligible trials had to report at least one of the predetermined outcomes of interest listed below. Eligible RCTs were included regardless of their primary objective or language of publication. Our methods were consistent with the previous steroid meta-analysis 5 and all 44 trials from that systematic review were included in our analysis.
Trial identification
We searched MEDLINE, EMBASE, and Cochrane CENTRAL using the pre-tested SIGN filters (http://www.sign.ac.uk) for RCTs. Our search terms included: cardiac surgery, cardiac surgical procedure, open-heart surgery, coronary artery bypass, mitral valve, aortic valve, heart valve, CPB, extracorporeal circulation, preoperative, and prophylactic, in combination with generic and trade names of steroid preparations. Finally, we reviewed the references of included studies for other potentially relevant studies and asked experts at our centre if they were aware of other relevant trials. See Supplementary Material B for the search strategy.
Trial selection
All references retrieved from the electronic search were uploaded into RefWorks (RefWorks-COS-2.0), and duplicates were removed. Remaining titles and abstracts were screened in duplicate by two independent reviewers and full text reports for all references deemed possibly relevant by any reviewer were retrieved and reviewed in duplicate to determine full eligibility criteria. Any disagreements were discussed; in all cases one person recognised an error. Reviewers' agreement for full text eligibility was assessed using Kappa statistic and was very good (k¼0.95).
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Data extraction and quality assessment
We collected descriptive data (e.g. patient population, surgery type, intervention, comparator) and markers of validity (e.g. blinding) from all selected trials. Outcomes of interest were mortality, myocardial infarction or injury (MI), neurological events (stroke/transient ischaemic attack), new onset atrial fibrillation, ICU stay, wound and infectious complications, and hospital length of stay. We accepted the authors' definitions for clinical outcomes. Two reviewers using pre-designed data collection forms independently extracted the data. Consensus was sought for discordant data and authors were contacted for missing data relevant to our study. The quality of individual trials was assessed based on methodological completeness, focusing on appropriate randomisation, double blinding, and adequate follow up (Jadad and colleagues 10 ). The 'Grading of Recommendations Assessment, Development and Evaluation' (GRADE) approach was used to rate the overall quality of evidence for individual clinical outcome effects by two reviewers. 11 The criteria potentially leading to downgrading of RCT evidence in the GRADE approach are study limitations, imprecision, indirectness, inconsistency, and potential publication bias.
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Statistical analysis
Clinical outcome data were extracted from each trial comparing patients receiving steroid therapy with the control group. We conducted a sensitivity analysis to assess the robustness of our results. The data were re-analysed after selecting only high-quality studies based on the absence of one or less methodological quality measures which we had a priori planned. Funnel plots were constructed for individual outcomes to evaluate possible publication bias through visual assessment of asymmetry.
Results
Selection of included studies
Fifty-six RCTs published between 1977 and 2015 fulfilled our eligibility criteria and were included in this meta-analysis. The trial selection process is shown in Supplementary Material A. All data were collected in duplicate. The median sample size was 60 patients (range, 13e7507). Two large recent RCTs contributed the majority of the included participants (74.9%) (SIRSe7507 patients and DECSe4494 patients). 6 
Sensitivity analyses
When the analyses were repeated to include only high quality large trials (>1000 patients), only the outcome of new atrial fibrillation significantly changed, where the effect of steroids became non-significant (n¼two trials, 11 989 patients, RR¼0.96; 95% CI, 0.90e1.01), compared with the small trials (n¼ 20 trials, 1959 patients, RR¼0.67; 95% CI 0.58e0.78) (P for interaction<0.00001) (Fig. 4) . All outcome analyses were heavily influenced by the two large trials, 6, 7 with effect weight ranging from 66.4% for hospital length of stay to 96.1% for renal failure. Analysing outcome effects after including only high-quality trials irrespective of trial size did not change the significance of our results.
Heterogeneity/subgroup analyses
Significant heterogeneity (I 2 >25%) was present for the outcomes of new onset atrial fibrillation, length of hospital stay, and length of ICU stay. We conducted subgroup analyses exploring the effect of surgery type, steroid type, and steroid dose on clinical outcomes to explore possible sources of heterogeneity. The effect of steroids on incidence of new onset atrial fibrillation did not differ based on steroid type (interaction P¼0.16) (Supplementary Material I) ; however, steroid dose (interaction P¼0.01) and surgery type (interaction P¼0.003) impacted the treatment effect. Trials of low dose steroids (13 studies, 13 248 patients) were associated with a smaller clinical benefit RR¼0.92; 95% CI, 0.87e0.98 whereas trials of high dose steroids (nine studies, 700 patients) were associated with a greater clinical benefit RR¼0.70; 95% CI, 0.57e0.87 Material J) . ICU length of stay also differed between the trials using high-dose steroids (n¼12 RCTs, 720 patients, MD¼À0.27; 95% CI, À0.43 to À0.12) resulting in a shorter ICU stay compared with trials using low-dose steroids (n¼19 RCTs, 13 028 patients, MD¼À0.02; 95% CI, À0.06e0.01) (interaction P¼0.002). Trials using methylprednisolone (17 studies, 8607 patients) were associated with a shorter ICU stay MD¼À0.03; 95% CI, À0.07e0.01 compared with The duration of hospital stay was longer in trials using methylprednisolone (n¼20 studies, 8567 patients, MD¼À0.11; 95% CI, À0.29e0.06) compared with trials using dexamethasone (n¼7 studies, 5099 patients, MD¼À0.85; 95% CI, À1.05 to À0.65) (interaction P¼0.00001) (Supplementary Material K). Hospital length of stay was also longer in trials using highdose steroids (n¼17 studies, 970 patients, MD¼À0.06; 95% CI, À0.43e0.31) compared with low-dose steroids (n¼14 studies, 12 911 patients, MD¼À0.43; 95% CI, À0.57 to À0.29) (interaction P¼0.07). Surgery type was not an effect modifier.
Publication bias
Funnel plots for mortality and new atrial fibrillation suggested possible publication bias. Funnel plots are available in Supplementary Material L.
Quality of evidence
The quality of evidence for the effect of steroids on several outcomes was downgraded using the GRADE approach and guidelines 11 ( Table 2) . Quality of evidence for mortality, neurological events, and renal failure were downgraded for imprecision, because the 95% CI included both no effect and a possible significant RR reduction. Quality of evidence for mortality and new atrial fibrillation were downgraded because of potential publication bias as suggested by the funnel plots, although the majority of the weight of the pooled estimate came from two large trials. The quality of evidence for new atrial fibrillation was also downgraded because of possible inconsistency in the presence of heterogeneity. Finally, ICU and hospital lengths of stay were downgraded because of heterogeneity not explained by subgroup analysis.
Discussion
The current body of literature provides improved reliability in our effect point estimates. Our data suggests that prophylactic administration of steroids does not result in significantly different mortality between groups and is associated with an increase in myocardial infarction or injury after onpump cardiac surgery. However, the 95% CI does not exclude the possibility of significant mortality benefit; if we were to repeat these experiments over and over again, the point estimates for 95% of the experiments would lie between a decrease in mortality by 29% or an increase in mortality by 1%. Therefore, with the potential publication bias, the evidence regarding mortality is considered low quality by GRADE criteria. The mortality-myocardial injury dissociation is hard to explain in a population where myocardial injury are expected to be associated with worst clinical outcomes. There was no significant effect of steroid use on neurological outcomes and renal failure with a moderate quality of evidence. Perioperative steroid use may decrease the incidence of atrial fibrillation after cardiac surgery (low quality of evidence). However, in the subgroup of large trials, steroids did not impact the incidence of atrial fibrillation suggesting that small, lower-quality trials may be driving this spurious result. 68 The OIS to detect a 25% RR reduction, assuming a 28% control event rate (the control event rate in our meta-analysis for new atrial fibrillation), would require more than 1700 patients with 80% power and a two-sided alpha of 0.01. Our analysis exceeded this IOS. 69 Surprisingly, rates of postoperative infectious complications were significantly lower in the steroid group (moderate quality of evidence) and the incidence of wound complications was similar in both groups (high quality evidence). Although ICU and hospital lengths of stay were significantly shorter with steroids based on moderate quality evidence, a 43-min difference on ICU length of stay and a 9-h difference on hospital length of stay is of questionable clinical relevance. The systemic inflammatory response after CPB use has been widely studied and described in the literature. 70, 71 The pathophysiology of this inflammatory response has been linked to the activation of platelets, neutrophils, and coagulation/kallikrein cascades through exposure of the blood to the CPB circuit surfaces. 71, 72 This has been shown to increase endothelial permeability and result in vascular and parenchymal damage, leading to postoperative complications including myocardial injury, respiratory failure, bleeding, and organ dysfunction. 3, 70, 73 Steroid drugs have been shown to reduce inflammation and related markers after CPB, which is the rationale of their use in the trials we analysed. 1, 70 Despite enrolling a total of 16 013 patients undergoing cardiac surgery in 56 trials of prophylactic steroid administration, it remains unclear whether they impact mortality. Given the 3.5% mortality in the control group, with 14 460 patients in trials looking at mortality as an outcome, our metaanalysis has only 66% power to detect a 20% RR reduction using a two-sided alpha of 5%. This lack of power highlights the importance of very large trials when trying to provide definitive answers regarding therapies for conditions associated with a low mortality rate. The significant increase in myocardial injury incidence with steroids contrasts with the trend towards a reduction in mortality. This finding was not observed in the previous metaanalysis. 5 There was significant heterogeneity between trials in defining and reporting this outcome. For example, in the SIRS trial that mandated postoperative creatinine kinasefraction MB (CK-MB) and ECG monitoring, the overall incidence of myocardial injury was 11.8% (885/7507 patients), using diagnostic criteria derived from the blinded data of the first 7000 participants. 6, 70 In contrast, in the DECS trial, MIs were defined by a biomarker elevation in association with new Qwaves or left bundle branch block on ECG, which resulted in a much lower incidence of 1.7% (74/4482 patients). 7 Differing MI definitions may have impacted the event incidence between trials, while absence of blinding in some trials may have led to differential reporting. Our results are particularly surprising, as there is evidence suggesting that steroid administration does not impact biomarker release in the management of MIs in the non-cardiac surgical setting. 74, 75 Cardiac tissue inflammation induced by the CPB and surgical trauma has been previously hypothesised to cause postoperative atrial fibrillation. 3, 4 In the subgroup of large trials in our meta-analysis, steroids did not reduce the incidence of atrial fibrillation after cardiac surgery. The finding of our quality, moderately confident in the effect estimate. The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low quality, confidence in the effect estimate is limited. The true effect may be substantially different from the estimate of the effect; very low quality, very little confidence in the effect estimate. The true effect is likely to be substantially different from the estimate of effect. y The 95% CI includes no effect and a potential 29% relative risk reduction. z The funnel plot suggests potential publication bias.
¶ The 95% confidence interval shows both no effect and relative risk reduction of 30%.
x Heterogeneity explained by large (n>1000) versus small (n<1000) trial. jj Although the funnel plot suggests potential publication bias, 83% of the weight of the pooled estimate comes from the two large trials. # The 95% CI includes no effect and a potential 32% relative risk reduction. ** High heterogeneity not explained by subgroup analysis.
previous meta-analysis that steroids reduce atrial fibrillation was based on a series of small trials. 5 With the most robust studies in this meta-analysis showing no effect, we conclude that steroids do not impact on atrial fibrillation. The aetiology of atrial fibrillation in this population is more complex than previously thought. The lower infection rate in the steroids group is counterintuitive. We believe that this result highlights the frequency with which patients with a postoperative inflammatory response are treated as if they had an infection.
Our results are mostly based on two large high quality RCTs (SIRS and DECS) which contribute approximately 11 000 patients to the total 16 000 patients. Publication bias is a major contributor when it comes to small trials, which is the large majority of trials included in the previous meta-analysis. 5 Additionally, many of the small trials included in the previous analysis were of low quality, with issues regarding randomisation, double blinding, and adequate follow-up (see Table 1 ). We believe that the difference in our findings compared to other reviews is largely because of more rigorous data and larger sample size. Our results, highly influenced by SIRS 6 and DECS, 7 are likely reflective of the true effect of prophylactic steroids in cardiac surgery.
Strengths and weaknesses
The strength of this systematic review is that it followed a rigorous methodology and an assessment in duplicate of eligibility criteria, data extraction, and outcome grading, with a high degree of agreement. Our search was comprehensive, using three large trial databases for published data and enquiring from specialists in the field about unpublished studies. Furthermore, although 57% of trials (35 out of 56 trials) focused on isolated CABG procedures, the proportion of total patient population derived from this group represented only 14%, whereas the rest of the population (86% or 13 720 out of 16 013 patients) came from trials including various CPB procedures leading to high generalisability. In contrast, the degree of inter-trial variability in defining and reporting clinical events, such as myocardial infarctions, threatens the validity of our results. The low event rates and the small proportion of trials reporting outcomes of renal failure, wound complications, and infectious complications limit our ability to draw conclusions about the effect of steroids on these outcomes. Further, we assumed a normal distribution for continuous outcomes (lengths of ICU and hospital stay) that were likely skewed. The trials included in this systematic review focused on different steroid protocols and included patients of different risk groups and surgery types. This introduces both clinical and methodological variability in our results.
In conclusion, this meta-analysis represents the most comprehensive assessment of current evidence with regards to the effects of steroids in patients undergoing cardiac surgery. The addition of two new large RCTs with rigorous methodologies greatly improves the reliability of our estimates of treatment effects and confidence in the evidence. After randomising 16 013 patients, steroid administration at the time of cardiac surgery has an unclear impact on mortality, increases the risk of myocardial injury, and the impact on atrial fibrillation should be viewed with caution given the large trials showed no effect. 
Author's contributions
